P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer.

Abstract

The present study was aimed to develop an effective nanoliposomal vaccine delivery system with P435 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. The nanoliposome formulation composed of DSPC/DSPG/Chol/DOPE and monophosphoryl lipid A was used as an adjuvant. Liposomal formulations were prepared and their physical properties were characterized. Anti-tumoral efficacy of formulations was evaluated by immunization of tumor-bearing BALB/c mice and the generated immune response was studied by using ELISpot and flow cytometry analysis. The results of the study demonstrated Lip + DOPE + P535 formulation caused the lowest tumor size and the longest survival time in TUBO mice model and could make it a promising candidate in developing effective vaccines against HER2-positive breast cancers.

• Authors: Niloofar Farzad, Nastaran Barati, Amir Abbas Momtazi-Borojeni, Mona Yazdani, Atefeh Arab, Atefeh Razazan, Sheida Shariat, Mercedeh Mansourian, Azam Abbasi, Zahra Saberi, Ali Badiee, Seyed Amir Jalali, Mahmoud Reza Jaafari
• Journal: Artificial cells, nanomedicine, and biotechnology (Artif Cells Nanomed Biotechnol) Vol. 47 Issue 1 Pg. 665-673 (Dec 2019) ISSN: 2169-141X [Electronic] England
• PMID: 30829072 (Publication Type: Journal Article)

Chemical References

• Cancer Vaccines
• Liposomes
• Peptides
• Erbb2 protein, mouse
• Receptor, ErbB-2

Topics

• Animals
• Cancer Vaccines (chemistry, immunology, pharmacology)
• Cell Line, Tumor
• Female
• Liposomes
• Mammary Neoplasms, Experimental (immunology, prevention & control)
• Mice, Inbred BALB C
• Nanoparticles (chemistry, therapeutic use)
• Peptides (chemistry, immunology, pharmacology)
• Receptor, ErbB-2 (chemistry, immunology, therapeutic use)